

Louise J Longworth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8383964/publications.pdf>

Version: 2024-02-01

59
papers

2,564
citations

218677

26
h-index

189892

50
g-index

59
all docs

59
docs citations

59
times ranked

3944
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. <i>Health Technology Assessment</i> , 2014, 18, 1-224.	2.8	276
2	Mapping to Obtain EQ-5D Utility Values for Use in NICE Health Technology Assessments. <i>Value in Health</i> , 2013, 16, 202-210.	0.3	202
3	The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. <i>Thorax</i> , 2016, 71, 493-500.	5.6	196
4	An empirical comparison of EQ-5D and SF-6D in liver transplant patients. <i>Health Economics (United Kingdom)</i> , 2014, 34, 1168-1178.	1.7	168
5	Assessing health-related quality of life pre- and post-liver transplantation: A prospective multicenter study. <i>Liver Transplantation</i> , 2002, 8, 263-270.	2.4	131
6	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-410.	2.8	130
7	A Review of Generic Preference-Based Measures of Health-Related Quality of Life in Visual Disorders. <i>Value in Health</i> , 2012, 15, 118-127.	0.3	112
8	Women and health care professionals' preferences for Down's Syndrome screening tests: a conjoint analysis study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2004, 111, 775-779.	2.3	83
9	An Exploratory Study to Test the Impact on Three Bolt-On Items to the EQ-5D. <i>Value in Health</i> , 2015, 18, 52-60.	0.3	74
10	Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. <i>Liver Transplantation</i> , 2003, 9, 1295-1307.	2.4	70
11	Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. <i>Value in Health</i> , 2011, 14, 102-109.	0.3	70
12	The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration. <i>Pharmacoeconomics</i> , 2015, 33, 993-1011.	3.3	70
13	EQ-5D in skin conditions: an assessment of validity and responsiveness. <i>European Journal of Health Economics</i> , 2015, 16, 927-939.	2.8	66
14	Measuring health-related utility. <i>European Journal of Health Economics</i> , 2005, 6, 253-260.	2.8	63
15	Binary Choice Health State Valuation and Mode of Administration: Head-to-Head Comparison of Online and CAPI. <i>Value in Health</i> , 2013, 16, 104-113.	0.3	61
16	Investigating women's preferences for intrapartum care: home versus hospital births. <i>Health and Social Care in the Community</i> , 2001, 9, 404-413.	1.6	59
17	Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. <i>Hepatology</i> , 2014, 60, 832-843.	7.3	59
18	Estimating utility data from clinical indicators for patients with stable angina. <i>European Journal of Health Economics</i> , 2005, 6, 347-353.	2.8	51

#	ARTICLE	IF	CITATIONS
19	Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. <i>Liver International</i> , 2019, 39, 2052-2060.	3.9	49
20	Preparatory study for the revaluation of the EQ-5D tariff: methodology report. <i>Health Technology Assessment</i> , 2014, 18, vii-xxvi, 1-191.	2.8	47
21	An assessment of validity and responsiveness of generic measures of health-related quality of life in hearing impairment. <i>Quality of Life Research</i> , 2013, 22, 2813-2828.	3.1	38
22	A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. <i>Value in Health</i> , 2016, 19, 885-891.	0.3	38
23	HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. <i>European Journal of Health Economics</i> , 2020, 21, 1421-1437.	2.8	38
24	Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. <i>British Journal of Psychiatry</i> , 2006, 188, 337-345.	2.8	36
25	Mapping Functions in Health-Related Quality of Life. <i>Medical Decision Making</i> , 2015, 35, 912-926.	2.4	35
26	Evaluation of content on EQ-5D as compared to disease-specific utility measures. <i>Quality of Life Research</i> , 2013, 22, 853-874.	3.1	26
27	Comparison of general practitioner records and patient self-report questionnaires for estimation of costs. <i>European Journal of Health Economics</i> , 2005, 6, 261-266.	2.8	22
28	Determining Priority for Liver Transplantation. <i>Applied Health Economics and Health Policy</i> , 2005, 4, 249-255.	2.1	22
29	Mapping the FACT-P to the Preference-Based EQ-5D Questionnaire in Metastatic Castration-Resistant Prostate Cancer. <i>Value in Health</i> , 2014, 17, 238-244.	0.3	21
30	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. <i>Pharmacoeconomics</i> , 2015, 33, 985-991.	3.3	21
31	Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?. <i>Value in Health</i> , 2016, 19, 210-217.	0.3	21
32	Views of the UK General Public on Important Aspects of Health Not Captured by EQ-5D. <i>Patient</i> , 2017, 10, 701-709.	2.7	21
33	When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development?. <i>Pharmacoeconomics</i> , 2013, 31, 137-149.	3.3	18
34	The Debrisoft® Monofilament Debridement Pad for Use in Acute or Chronic Wounds: A NICE Medical Technology Guidance. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 583-594.	2.1	17
35	An Assessment of the Impact of Informative Dropout and Nonresponse in Measuring Health-Related Quality of Life Using the EuroQol (EQ-5D) Descriptive System. <i>Value in Health</i> , 2005, 8, 53-58.	0.3	15
36	An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies. <i>Value in Health</i> , 2016, 19, 53-59.	0.3	14

#	ARTICLE	IF	CITATIONS
37	Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. <i>Quality of Life Research</i> , 2016, 25, 275-281.	3.1	14
38	Bridging the gap between methods research and the needs of policy makers: A review of the research priorities of the National Institute for Health and Clinical Excellence. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 180-187.	0.5	13
39	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 106.	2.4	13
40	An Economic Evaluation of Pediatric Small Bowel Transplantation in the United Kingdom. <i>Transplantation</i> , 2006, 82, 508-515.	1.0	11
41	NICE Methodology for Technology Appraisals. <i>Pharmacoeconomics</i> , 2008, 26, 729-732.	3.3	9
42	Does Responsibility Affect the Public's Valuation of Health Care Interventions? A Relative Valuation Approach to Health Care Safety. <i>Value in Health</i> , 2012, 15, 690-698.	0.3	9
43	How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?. <i>Medical Decision Making</i> , 2018, 38, 306-318.	2.4	9
44	PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 230-235.	0.5	7
45	The cardiac output optimisation following liver transplant (COLT) trial: a feasibility randomised controlled trial. <i>Hpb</i> , 2020, 22, 1112-1120.	0.3	7
46	Survival gain after liver transplantation for patients with alcoholic liver disease: a comparison across models and centers. <i>Transplantation</i> , 2003, 76, 1479-1486.	1.0	6
47	Elicitation of Health-Related Utility in Perianal Fistula in Crohn's Disease. <i>Patient</i> , 2019, 12, 339-348.	2.7	5
48	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. <i>Journal of Medical Economics</i> , 2015, 18, 851-857.	2.1	4
49	Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. <i>European Journal of Health Economics</i> , 2021, 22, 1301-1309.	2.8	3
50	Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 119-131.	2.1	3
51	Cost-effectiveness of upcoming treatments for hepatitis C: We need to get the models right. <i>Journal of Hepatology</i> , 2014, 61, 453-454.	3.7	2
52	Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study. <i>European Journal of Cancer, Supplement</i> , 2021, 16, 14-23.	2.2	2
53	Effect of post-operative goal-directed fluid therapy (GDFT) on organ function after orthotopic liver transplantation: Secondary outcome analysis of the COLT randomised control trial. <i>International Journal of Surgery</i> , 2022, 99, 106265.	2.7	2
54	An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib. <i>Value in Health</i> , 2022, , .	0.3	2

#	ARTICLE	IF	CITATIONS
55	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. <i>Medical Decision Making</i> , 2015, 35, NP1-NP8.	2.4	1
56	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 437-443.	2.1	1
57	Estimation of Health-Related Utilities for ¹⁷⁷ Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities. <i>Pharmacoeconomics - Open</i> , 2021, 5, 715-725.	1.8	1
58	Exploring what lies behind public preferences for avoiding health losses caused by lapses in healthcare safety and patient lifestyle choices. <i>BMC Health Services Research</i> , 2013, 13, 249.	2.2	0
59	COMPARISON OF METHODS FOR ESTIMATING CONTEMPORARY COSTS: AN APPLICATION TO LIVER TRANSPLANTATION IN THE UNITED KINGDOM. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 620-628.	0.5	0